TEPMETKO has been studied in VISION, the largest clinical trial of patients with METex14 skipping NSCLC*^,**^1,2

Study design

Key inclusion criteria^1,2

Advanced/metastatic NSCLC (all histologies)
Positive detection of METex14 skipping by liquid and/or tissue biopsy
Treatment-naïve and previously treated patients

VISION: A single-arm, open-label, multicenter, non-randomized, multi-cohort study¹

Cohort A

(primary) 

n=152

Cohort B

(confirmatory; patients  with >18 months’ follow-up)

n=161

Cohort A+C

N=313^†

TEPMETKO 450 mg QD^††

TISSUE BIOPSY (n=208)

Treatment naïve (n=111) 

Previously treated (n=97)

LIQUID BIOPSY (n=178)

Treatment naïve (n=95) 

Previously treated (n=83)

Primary efficacy outcome: confirmed overall response rate by RECIST v1.1 as evaluated by IRC
Additional efficacy outcomes: duration of response, progression-free survival, overall survival

High patient numbers: expanding cohorts have taken the METex14 skipping NSCLC population to 313 patients (Cohorts A+C)¹

Robust subgroup analyses: the sizeable patient numbers in pre-defined subgroups allowed for the examination of outcomes in specific population¹

Patient characteristics

The VISION study assessed TEPMETKO in 313 patients with METex14 skipping NSCLC identified by tissue or liquid biopsy^1,3

Choice of biopsy to assess METex14 skipping was flexible and investigator-led – more patients were enrolled based on a positive result in tissue biopsy than in liquid biopsy (both analyzed with next-generation sequencing assays)^1,3,4

Tumor burden was higher in patients who enrolled based on liquid biopsy:^‡3

Median tumor load

55.2 mm for patients diagnosed via Tissue Biopsy

vs.

Median tumor load

67.1 mm for patients diagnosed via Liquid Biopsy

TEPMETKO delivered an effective response first-line and beyond¹

With TEPMETKO, give your patients more moments that matter

3–4% of your patients with NSCLC may have METex14 skipping^2,5,6

Explore the importance of timely targeted therapy for your NSCLC patients

Learn more about the unmet need

TEPMETKO may offer substantially increased mDOR vs. capmatinib⁷

A matching-adjusted indirect comparison (MAIC) of TEPMETKO vs. capmatinib has shown improved mDOR, mOS and mPFS⁷

Learn more about MAIC outcomes

TEPMETKO demonstrated a manageable safety profile that maintained QoL^**1,8–11

Most common AEs were mild to moderate⁹

Learn more about safety, dosing and QoL

*The overall patient population of N=313 in the VISION study comprises treatment-naïve and previously treated patients with METex14 skipping NSCLC¹
**Cohort A follow-up >35 months; Cohort C follow-up >18 months; median follow-up of Cohorts A+C 32.6 months¹
^†24% of patients who tested positive for METex14 skipping alteration via both tissue and liquid biopsy are included in both analyses³
^††TEPMETKO is administered as 450 mg tepotinib (2 × 225 mg tablets); equivalent to 500 mg tepotinib hydrochloride hydrate (2 × 250 mg tablets)^12,13
^‡Median tumor loads are for N=313 treatment-naïve and previously treated patients enrolled based on tissue and/or liquid biopsy. Patients enrolled based on liquid biopsy had a higher tumor burden than those enrolled based on tissue biopsy³

Abbreviations

AE, adverse event; IRC, independent review committee; MAIC, matching-adjusted indirect comparison; mDOR, median duration of response; MET, mesenchymal-epithelial transition; METex14; mesenchymal epithelial transition factor exon 14; mOS, median overall survival; mPFS, median progression-free survival; NSCLC, non-small cell lung cancer; QD, once daily; QoL, quality of life; RECIST, Response Evaluation Criteria in Solid Tumors

References

Mazieres J et al. JAMA Oncol 2023; 9:1260−1266.
Paik PK et al. N Engl J Med 2020; 383:931–943.
Rolfo C et al. Presented at: European Society for Medical Oncology (ESMO) 2023; 20–24 October 2023; Madrid, Spain (Poster no. 1382P).
Le X et al. Clin Cancer Res 2022; 28:1117–1126.
Salgia R. Mol Cancer Ther 2017; 16:555–565.
Tong JH et al. Clin Cancer Res 2016; 22:3048–3056.
Pfeiffer BM et al. Presented at: IASLC World Conference on Lung Cancer (WCLC) 2023; 9−12 September 2023; Virtually and Singapore (Poster no. 1312).
Mazieres J et al. JAMA Oncol 2023; 9:1260–1266 (supplementary appendix 2).
Paik PK et al. Presented virtually at: American Society of Clinical Oncology (ASCO) Annual Meeting 2023; 2–6 June 2023; Chicago, IL, USA (Abstract no. 9060).
Veillon R et al. Clin Lung Cancer 2022; 23:320–332.
Ahn L et al. Clin J Oncol Nurs 2022; 26:543–551.
Paik PK et al. N Engl J Med 2020; 383:931–943 (supplementary appendix).
TEPMETKO® (tepotinib) [prescribing information], EMD Serono, Inc., Rockland, MA; 2024.

This website is an international information resource intended only for healthcare professionals from outside the European Economic Area (EEA), the US, Puerto Rico and Canada who are interested in information on TEPMETKO. The information on this website contains educational and promotional material. By clicking on 'I'm a healthcare professional' you are declaring and confirming that are you a healthcare professional and have read and understood this.

GL-TEP-00506 | April 2025

This website is an international information resource intended only for Healthcare Professionals from outside the European Economic Area (EEA), the US, Puerto Rico
and Canada who are interested in information on TEPMETKO.

TEPMETKO has been studied in VISION, the largest clinical trial of patients with METex14 skipping NSCLC*,**1,2

Study design

Key inclusion criteria1,2

VISION: A single-arm, open-label, multicenter, non-randomized, multi-cohort study1

Cohort A

Cohort B

Cohort A+C

TEPMETKO 450 mg QD††

TISSUE BIOPSY (n=208)

LIQUID BIOPSY (n=178)

Patient characteristics

The VISION study assessed TEPMETKO in 313 patients with METex14 skipping NSCLC identified by tissue or liquid biopsy1,3

Median tumor load

55.2 mm for patients diagnosed via Tissue Biopsy

Median tumor load

67.1 mm for patients diagnosed via Liquid Biopsy

With TEPMETKO, give your patients more moments that matter

3–4% of your patients with NSCLC may have METex14 skipping2,5,6

TEPMETKO may offer substantially increased mDOR vs. capmatinib7

TEPMETKO demonstrated a manageable safety profile that maintained QoL**1,8–11

Abbreviations

References

Prescribing Information

Cookie Disclamer

TEPMETKO has been studied in VISION, the largest clinical trial of patients with METex14 skipping NSCLC*^,**^1,2

Key inclusion criteria^1,2

VISION: A single-arm, open-label, multicenter, non-randomized, multi-cohort study¹

TEPMETKO 450 mg QD^††

The VISION study assessed TEPMETKO in 313 patients with METex14 skipping NSCLC identified by tissue or liquid biopsy^1,3

3–4% of your patients with NSCLC may have METex14 skipping^2,5,6

TEPMETKO may offer substantially increased mDOR vs. capmatinib⁷

TEPMETKO demonstrated a manageable safety profile that maintained QoL^**1,8–11